StreetInsider.com News Articles

UBS Assumes Guardant Health (GH) at Buy

Wed, 09 Sep 2026 06:08:44 -0400

UBS analyst Douglas Schenkel assumes coverage on Guardant Health (NASDAQ: GH) with a Buy rating and a price target of $225.00.

For an analyst ratings summary and ratings history on Guardant Health click here. For more ratings news on Guardant Health click here.

Shares of Guardant Health closed at $160.98 yesterday.

Rothschild Redburn Starts Guardant Health (GH) at Buy

Tue, 08 Sep 2026 03:24:25 -0400

Rothschild Redburn analyst Jamie Clark initiates coverage on Guardant Health (NASDAQ: GH) with a Buy rating and a price target of $203.00.

The analyst comments: “Guardant Health is the leader in testing via liquid biopsy. Shield is the first CRC screening blood test to receive FDA approval, could broaden into a multi-cancer detection test and likely represents the company’s single largest opportunity. Its Guardant360 treatment selection test allows tumour-sequencing via a blood test and is currently its largest franchise. Recent approval of the latest version, Guardant360 Liquid CDx, should spur continued volume and price gains. Reveal, its tumour-naïve MRD test, is

Rothschild Redburn Starts Guardant Health (GH) at Buy

Tue, 08 Sep 2026 03:24:25 -0400

Rothschild Redburn analyst Jamie Clark initiates coverage on Guardant Health (NASDAQ: GH) with a Buy rating and a price target of $203.00.

Guardant Health (GH) call put ratio 1 call to 6.9 puts with a focus on September 150 and 160 puts

Mon, 31 Aug 2026 05:31:17 -0400

Guardant Health (NASDAQ: GH) 30-day option implied volatility is at 53; compared to its 52-week of 45 to 85. Call put ratio 1 call to 6.9 puts with a focus on September 150 and 160 puts.

Form 4 Guardant Health, Inc. For: Aug 26 Filed by: Eltoukhy Helmy

Thu, 27 Aug 2026 19:47:00 -0400

si-local-file:///var/storage/secattach/20260827/26991708.html

Form 4 Guardant Health, Inc. For: Aug 26 Filed by: Eltoukhy Helmy

Thu, 27 Aug 2026 19:47:00 -0400

si-local-file:///var/storage/secattach/20260827/26991708.html

TD Cowen Reiterates Buy Rating on Guardant Health (GH), $245M Patent Judgment Risks Seen as Managable

Tue, 25 Aug 2026 07:34:41 -0400

TD Cowen analyst Dan Brennan reiterated a Buy rating and $210.00 price target on Guardant Health (NASDAQ: GH).

The analyst commented: "A federal court entered final judgment in TwinStrands patent case against GH resulting in ~$245M of damages & a 6% royalty on certain products thru 2033. GH traded -4.4% in a weak tape. While a negative GH sees multiple ways to challenge/mitigate the impact & in a 'worst-case' (challenges don't succeed) expects assay redesigns can cut future royalties to 0%. We view the risks as manageable"

For an analyst ratings summary and ratings history on Guardant Health click here. For

Form 4 Guardant Health, Inc. For: Aug 21 Filed by: Talasaz AmirAli

Mon, 24 Aug 2026 17:22:00 -0400

si-local-file:///var/storage/secattach/20260824/26969182.html

Form 4 Guardant Health, Inc. For: Aug 21 Filed by: Talasaz AmirAli

Mon, 24 Aug 2026 17:22:00 -0400

si-local-file:///var/storage/secattach/20260824/26969182.html

Form 4 Guardant Health, Inc. For: Aug 21 Filed by: MIGNONE ROBERTO

Mon, 24 Aug 2026 17:21:00 -0400

si-local-file:///var/storage/secattach/20260824/26969176.html

Form 4 Guardant Health, Inc. For: Aug 21 Filed by: MIGNONE ROBERTO

Mon, 24 Aug 2026 17:21:00 -0400

si-local-file:///var/storage/secattach/20260824/26969176.html

Guardant Health to appeal Delaware patent ruling by TwinStrand

Mon, 24 Aug 2026 14:44:46 -0400

Guardant Health (Nasdaq: GH) announced it will appeal a final judgment from the U.S. District Court for the District of Delaware related to intellectual property claims brought by TwinStrand Biosciences, Inc. and the University of Washington. Execution of the judgment and collection of potential royalties will be stayed pending the appeal.

The court order, which defined the scope of royalties based on products that existed at the time of the 2023 trial, excludes current versions of Guardant's Reveal and Shield products, as many earlier versions have since been discontinued or upgraded. Guardant also stated it has validated design improvements to its

Guardant Health to appeal Delaware patent ruling by TwinStrand

Mon, 24 Aug 2026 14:44:46 -0400

Guardant Health to Appeal Federal District Court Judgment

Mon, 24 Aug 2026 14:44:00 -0400

Current Guardant Reveal, Shield products excluded from final District Court order
Company has validated Guardant360 design improvements to exclude impact of potential royalties

PALO ALTO, Calif.--(BUSINESS WIRE)-- Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will appeal the final judgment from the U.S. District Court for the District of Delaware related to intellectual property claims brought against Guardant by TwinStrand Biosciences, Inc. and University of Washington, with execution of the final judgment and collection of potential royalties stayed pending appeal.